Clinical Trials Logo

Smoldering Multiple Myeloma clinical trials

View clinical trials related to Smoldering Multiple Myeloma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03952832 Withdrawn - Clinical trials for Smoldering Plasma Cell Myeloma

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

Start date: December 11, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well leflunomide works in treating patients with high-risk smoldering multiple myeloma. Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03591614 Withdrawn - Myeloma Clinical Trials

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

Start date: December 1, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to study the safety and preliminary efficacy of a dendritic cell DKK1 vaccine against myeloma. Dendritic cells are immune cells that are collected from the blood of the patient at Case Western Reserve Medical Center and then brought into contact with DKK1, a molecule that is present of myeloma cells but not to a significant amount on other cells except for the prostate and the placenta. It is an investigational (experimental) vaccine that based on studies in the laboratory and in mice is expected to work by presentation of DKK1 to anticancer immune cells via dendritic cells leading to an immune attack on myeloma cells. It is experimental because it is not approved by the Food and Drug Administration (FDA).

NCT ID: NCT01660997 Withdrawn - Multiple Myeloma Clinical Trials

MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma

Start date: July 30, 2012
Phase: Phase 2
Study type: Interventional

Background: - Smoldering multiple myeloma (SMM) is a condition that can lead to multiple myeloma, a type of blood cancer. In many high-risk cases, SMM can develop into multiple myeloma in less than 2 years. The current standard of care for SMM is follow-up without treatment until multiple myeloma develops. However, some drugs are being studied to see if they can slow down or prevent the disease from progressing. One such drug is MLN9708. It has shown some results against multiple myeloma. Researchers want to combine MLN9708 with dexamethasone to see how it works against high-risk SMM. Objectives: - To see if MLN9708 with dexamethasone is a safe and effective treatment for high-risk smoldering multiple myeloma. Eligibility: - Individuals at least 18 years of age who have high-risk smoldering multiple myeloma. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and a bone marrow biopsy may also be performed. - Participants will take MLN9708 and dexamethasone on a regular schedule for 28 days. They will take each drug four times at regular intervals during each cycle of treatment. - Treatment will be monitored with frequent blood tests and imaging studies. - Participants will have 12 cycles of treatment. After four cycles, patients will be recommended to have their own stem cells collected and stored. This will allow the potential application of a highdose melpahalan/autologous stem cell transplant in the event there is a need in the future (not part of this study). - After 12 cycles, participants will keep taking MLN9708 as long as the disease does not progress and the side effects are not too severe.

NCT ID: NCT01571726 Withdrawn - Multiple Myeloma Clinical Trials

Imaging Studies and the Development of Multiple Myeloma

Start date: March 27, 2012
Phase: Phase 2
Study type: Interventional

Background: - Multiple myeloma (MM) is a type of malignant blood cancer. It affects the plasma cells, which help produce antibodies and fight infection. MM is nearly always preceded by a pre-malignant state, monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). Currently, it is not possible to predict when someone with MGUS or SMM will develop MM. Also, the disease changes in those early states are not well understood. Researchers want to look at imaging studies of people with MGUS, SMM, and MM. They will study whether the growth of blood vessels can be used to predict disease progression. Objectives: - To use imaging studies to evaluate disease progression in multiple myeloma. Eligibility: - Individuals at least 18 years of age who have MGUS, SMM, or newly diagnosed MM. Design: - Participants will be screened with a physical exam and medical history. They will also have blood and urine tests, and provide bone marrow samples. - Participants will have positron emission tomography (PET) scans with the new contrast agent [18]F-Fluciclatide. The contrast agent is intended to show patterns of increased vessel growth in the bone marrow. - Participants will also have a magnetic resonance imaging (MRI) scan. This scan will be done according to standard procedures. - Researchers will compare these scans with blood tests and other clinical information to study disease progression of MGUS, SMM, and MM.

NCT ID: NCT00503763 Withdrawn - Clinical trials for Smoldering Multiple Myeloma

Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma

PSMMSS
Start date: September 2007
Phase: Phase 2
Study type: Interventional

The aim of the study is to evaluate the effect of statin administration on the course of progressive Smoldering Multiple Myeloma.